The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1074
March 20, 2000
View Complete Issue         Table of Contents 2019 
Curosurf
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Curosurf
March 20, 2000 (Issue: 1074)
Poractant alfa intratracheal suspension (Curosurf), a formulation of surfactant available in Europe since 1989, has been approved by the FDA for treatment of neonatal respiratory distress syndrome (RDS).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Curosurf
Article code: 1074b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.